Ortoma Q1’24: Continued progress and 510(k) approval - Redeye

Redeye provides a short comment on Ortoma’s Q1 report this morning. There are several essential steps in the quarter. The net sales figure came in better than expected when excluding a milestone payment that we expected. The more important event is the 510(k) approval for the AI-assisted OTS™ Hip in the USA. The liquid assets at the end of the quarter were SEK 41.1m. The Q1 showed costs that were lower than expected. We expect to make small changes to our estimates with a slight positive bias as net sales (product sales are better than expected) on our current Base case of SEK 18.0 per share.

Länk till analysen i sin helhet: https://www.redeye.se/research/1010185/ortoma-q124-continued-progress-and-510k-approval?utm_source=finwire&utm_medium=RSS